ESTRO 2024 - Abstract Book

S1887

Clinical - Mixed sites, palliation

ESTRO 2024

therapeutic dose coverage to GTV

Diagnostic CT 18 months after SBRT with evidence of persistent good partial response.

Conclusion:

SBRT represents an effective option as metastasis-directed therapy for adrenal gland metastases in oligometastatic patients. A prescribing dose corresponding to a BED10 >70 Gy correlates with improved local control.

Keywords: Oligometastatic disease, SABR

1067

Digital Poster

Treatment and toxicity in DPYD-deficiency patients receiving 5-fluoruracil based chemoradiotherapy

Elgin Hoffmann 1 , Andreas Toepell 1 , Andreas Peter 2 , Christiana Roggia 3 , Simon Böke 1 , Chiara De-Colle 1 , Marc Steinle 1 , Maximilian Niyazi 1 , Cihan Gani 1 1 Eberhard-Karls University Tübingen, Department of Radiation Oncology, Tübingen, Germany. 2 Eberhard-Karls University Tübingen, Institute for Clinical Chemistry and Pathobiochemistry, Tübingen, Germany. 3 Eberhard-Karls University Tübingen, Institute of Medical Genetics and Applied Genomics, Tübingen, Germany